In this conversation with Alicia Morgans, Simpa Salami discusses transcriptomic heterogeneity in multifocal prostate cancer and factors predisposing certain prostate cancer-focused to metastasis. Simpa Salami is a Prostate Cancer Foundation (PCF) Young Investigator Award recipient. Highlighting key takeaways from two research studies, Dr. Salami also shares how the PCF funding has supported…
APCCC 2024, Advanced Prostate Cancer, radical prostatectomy, pelvic lymph node dissection, cN1 disease, Extended pelvic lymph node dissection, RAVES trial, RADICALS-RT trial, GETUG 17 trial,…
APCCC 2024, prostate cancer, Radiation Therapy Schedules for prostate cancer, Locally Advanced Prostate Cancer, GETUG-AFU 18 trial, dose-escalated external beam radiotherapy, ultrahypofractionation, ultrahypofractionation via stereotactic…
APCCC 2024 management of metastatic hormone sensitive prostate cancer (mHSPC), synchronous high-volume mHSPC, HORRAD trial, de novo mHSPC, STAMPEDE Arm H, STOPCAP collaboration.
APCCC 2024 metastatic hormone sensitive prostate cancer (mHSPC), patients with mHSPC that should receive “total therapy”, External beam radiation, abiraterone, enzalutamide, apalutamide, darolutamide.
APCCC 2024 how to manage patients with synchronous low-volume mHSPC, combination systemic therapy plus local treatment of the primary for synchronous low-volume mHSPC, ADT alone…
APCCC 2024 prognostic factors for the management of patients with metastatic hormone-sensitive prostate cancer (mHSPC), predictive factors for the management of patients with mHSPC
APCCC 2024 treatment for biochemical recurrence/PSA persistence, stereotactic or whole pelvis radiotherapy for patients with biochemical recurrence, APCCC key questions.
Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data…
APCCC 2024, Biochemical Relapse, Salvage Radiation Therapy, androgen deprivation therapy (ADT), biochemical recurrence after radical prostatectomy, Oncotype DX, Prolaris, ProMark, Decipher genomic classifier score, utilization…
APCCC 2024, prostate cancer, prostate cancer biochemical recurrence, Androgen Receptor Antagonist Monotherapy, EMBARK trial, enzalutamide, bicalutamide, leuprolide acetate, Gynecomastia after prostate cancer treatment, antineoplastic therapy,…
